TERT Promoter Mutations Predict Worse Survival in Laryngeal Cancer Patients
Yiping Qu,Siwen Dang,Kexia Wu,Yuan Shao,Qi Yang,Meiju Ji,Bingyin Shi,Peng Hou
DOI: https://doi.org/10.1002/ijc.28728
2014-01-01
International Journal of Cancer
Abstract:Head and neck squamous cell cancer (HNSCC) is estimated to be the sixth most common malignant tumor worldwide. Of which, laryngeal cancer is the second most common HNSCC.1 The definite cause of laryngeal cancer is not yet determined, although some risk factors, such as tobacco and alcohol consumption, genetic and epigenetic alterations are believed to be linked with the development of this disease.2, 3 Telomerase reverse transcriptase (TERT) gene, which encodes the catalytic subunit of telomerase, has been demonstrated to be up-regulated in human cancers, contributing to carcinogenesis.4 Recently, two recurrent somatic mutations (1,295,228 C>T and 1,295,250 C>T, hereafter named C228T and C250T, respectively) in the TERT gene promoter have been frequently reported in various human cancers, including melanoma (71%), thyroid cancer (22–51%), bladder cancer (84.6%) and glioblastoma (83.8%).5-8 In contrast, a very low frequency of these mutations has been found in certain cancers, particularly in esophageal squamous cell carcinoma (1.6%) and gastric cancer (0.7%).8-10 Importantly, these two mutations conferred a 2- to 4-fold increase in TERT transcriptional activity.5 Moreover, they have been demonstrated to be absent in benign tumors and normal subjects, implicating their potentially critical roles in human carcinogenesis. Although a previous study showed frequent TERT promoter mutations in head and neck cancers especially tongue cancer (47.8% of 23 tumors),8 only 10 patients with laryngeal cancer were included in this study, and these mutations were absent in these samples. In this study, a total of 235 laryngeal cancer tissues were randomly obtained from the First Affiliated Hospital of Xi'an Jiaotong University School of Medicine, with approval by the institutional review board of the Hospital. Relevant clinicopathological data were obtained from the patients' files or by interview with the patients or their relatives, and are presented in Supported Information Table 1. Genomic DNA was isolated using standard protocols of protease K digestion, phenol-chloroform extraction and ethanol precipitation. The TERT proximal promoter, which contains the sites of C228T and C250T mutations, was amplified from sample DNA by a pyrosequencing approach using primers and conditions previously described.10 The PCR product was sequenced on a PyroMark Q24 system using PyroMark Gold Q24 reagent (Qiagen,Xi'an/China). Sanger sequencing was then performed to confirm the results of pyrosequencing using the same primer pair as for pyrosequencing assay. As shown in Figures 1a and 1b, TERT promoter mutations were present in 27% (64 of 235) of the laryngeal cancer samples. TERT C250T mutations were more common (56 of 235) than C228T mutations (8 of 235), and these two mutations were mutually exclusive in this cancer. This finding was consistent with a hypothesis from a recent study that TERT promoter mutations occurred frequently in a subset of tumors derived from cells with low rates of self-renewal, such as melanomas, hepatocellular carcinomas, liposarcomas, urothelial carcinomas, squamous cell carcinomas of the tongue and subtypes of gliomas.8 Next, we investigated the association of TERT promoter mutations with clinicopathological characteristics of laryngeal cancer patients. As shown in Table 1, these two mutations did not significantly correlate with any clinicopathological variables in laryngeal cancer. However, TERT promoter mutations, particularly C250T mutation in the smoking patients (47 of 130) was more frequent than that in the non-smoking patients (9 of 49), although no statistical significance was noted (p =0.09). In addition, univariate survival analysis showed that TERT promoter mutations were significantly associated with poor survival with a hazard ratio (HR) of 1.52 (95% CI, 1.05–2.20; p =0.03) (Supporting Information Table 2). We also used Kaplan–Meier survival curves to further determine the effect of these two mutations on the survival of laryngeal cancer patients. Similar to the findings in Supporting Information Table 2, TERT promoter mutations significantly affect the overall survival of laryngeal cancer patients. The cases with TERT promoter mutations had significantly shorter survival times than those with wild-type TERT (72.2 months vs. 78.2 months on average; p =0.04) (Fig. 1c, left panel). Further analysis revealed that TERT C250T mutation was significantly associated with worse survival of laryngeal cancer patients as compared with wild-type TERT (69.2 months vs. 78.2 months on average, p =0.01) (Fig. 1c, right panel). Surprisingly, although the difference did not reach statistically significant, the cases with TERT C228T mutation had longer survival times than those with wild-type TERT (97.8 months vs. 78.2 months on average; p =0.37) (Fig. 1c, middle panel). Nevertheless, the limited number of TERT C228T mutation may yield such inconclusive results. Therefore, further investigation need to be conducted to determine its prognostic value. Next, we wanted to explore whether the prognostic value of TERT promoter mutations as found in univariate analysis is attributable to its relationship with other clinicopathological factors or whether these mutations themselves contribute independently to prognosis. Thus, the independent relationship of these mutations with overall survival was studied with Cox multivariate repression analysis. Our data indicated that TERT promoter mutations were significant predictors of poor prognosis for laryngeal cancer patients (HR = 1.66; 95% CI, 1.13–2.45; p = 0.01) as an independently variable with respect to age, tumor localization, TNM stage, tumor invasion, lymph node metastasis and smoking history (Supporting Information Table 2). In conclusion, we found common TERT promoter mutations in a large cohort of laryngeal cancers and demonstrated that these mutations, particularly TERT C250T mutation was strongly associated with worse survival of laryngeal cancer patients. These observations raise the possibility that TERT prompter mutations may represent important genetic driver events, and may be potentially valuable prognostic markers in this cancer. Yours sincerely,Yiping Qu Siwen Dang Kexia Wu Yuan Shao Qi Yang Meiju Ji Bingyin Shi Peng Hou Additional Supporting Information may be found in the online version of this article. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.